Nasoxyl (Xylometazoline Hydrochloride)

Xylometazoline is a selective α1‑ and α2‑adrenergic receptor agonist. When applied to the nasal mucosa it stimulates these receptors on vascular smooth muscle, causing vasoconstriction, which decreases mucosal edema and opens the nasal passages. The effect is local and begins within minutes.

The appropriate dose of Nasoxyl is determined by the prescribing healthcare professional based on the patient’s age, condition and response. Typically, one or two sprays per nostril every 10‑12 hours are used, but the exact regimen should follow the prescriber’s instructions and the product label.

Safety data for xylometazoline in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using Nasoxyl to weigh potential benefits against possible risks.

To request Nasoxyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasoxyl’s active ingredient, xylometazoline, belongs to the imidazoline class, offering rapid onset and a duration of action of up to 12 hours. Compared with phenylephrine‑based sprays, xylometazoline generally provides longer relief with a lower incidence of systemic cardiovascular effects, but all topical decongestants share a risk of rebound congestion if used beyond three days.

Nasoxyl should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children. Do not freeze the product.

Nasoxyl is applied as a nasal spray. The user should gently blow the nose to clear excess mucus, then insert the tip of the spray bottle into one nostril, close the opposite nostril, and press the pump to deliver the recommended number of sprays. The process is repeated for the other nostril if required.

The most serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, significant elevation of blood pressure or hypertensive crisis, and rare severe allergic reactions such as anaphylaxis or nasal ulceration. Patients experiencing these symptoms should discontinue use and seek immediate medical attention.

Nasoxyl should be avoided in individuals with known hypersensitivity to xylometazoline or any formulation components, in children under six years of age unless directed by a clinician, and in patients with uncontrolled hypertension, severe coronary artery disease, or those taking monoamine oxidase inhibitors. Consultation with a healthcare professional is advised before use.